Phase I safety, pharmacokinetic, and pharmacodynamic study of KW-0761 in CC chemokine-receptor 4 expressing peripheral T-cell lymphoma.

Trial Profile

Phase I safety, pharmacokinetic, and pharmacodynamic study of KW-0761 in CC chemokine-receptor 4 expressing peripheral T-cell lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs Mogamulizumab (Primary)
  • Indications Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 01 Oct 2017 Results of pooled data from two trial (NCT00920790 and NCT00355472) assessing efficacy of mogamulizumab in patient with relapsed adult T-cell leukemia-lymphoma, were published in the Cancer Science.
    • 12 Dec 2011 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 12 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top